Efficacy Analysis of Temozolomide in Treatment of Recurrent Brain Glioma
LYU Dong-Fang
WANG Xue-Li
WU Jiang
YUE Xiang-Yong
Abstract：Objective To evaluate the efficacy and safety of temozolomide ( TMZ) in the treatment of recurrent brain gliomas. Methods A total of 42 patients with recurrent brain glioma were treated by TMZ with a initial dosage of 150 mg/m2 once a day for durative 5 days and 28 days as a treatment cycle. The clinical curative effect and complications were observed after 3 cycles of treatment. Results The group of 42 patients was successfully completed chemotherapy, and no treatment-re-lated death occurred during the therapy. There were 15 patients with reduced tumor sizes, and the partial remission ( PR) rate was 35.7% (15/42); 16 patients with stable diseases, and the stable disease (stable disease, SD) rate was 38. 1%(16/42);11 patients with tumor growth, and the progression (progressive disease, PD) rate was 26. 2% (11/42). Efficien-cy rate (CR+PR) in the group was 35. 7% (15/42), and disease control rate (CR+PR+SD) was 73. 8% (31/42). Twenty-one patients had nausea and vomiting, and six patients had toxic reactions, such as decreased white blood cells, neu-trophils, and platelets. Two patients showed different degrees of hair loss, but no damage of liver, kidney, and lung. Conclu-sion TMZ is an ideal chemotherapy drug that can be used to treat recurrent brain glioma, because it has a certain clinical effect and less adverse reaction.
Keywords：TemozolomideRecurrenceBrain gliomaTreatment outcome
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 99-101 )